46 AVENUE DE LA GRANDE ARMEE, PARIS, I0
Venglustat accepted for priority review in the US to treat type 3 Gaucher disease
Belén Garijo appointed as Director and Chief Executive Officer
Successfully prices 2.3 billion of bond issue
Cenrifki (tolebrutinib) recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without relapses
Q1 2026: Double-Digit Sales and Business EPS Growth
Lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP
Rezurock Approved in the EU to Treat Chronic Graft-Vs-Host Disease
Venglustat Earns Breakthrough Therapy Designation in the US for Type 3 Gaucher Disease
Annual and Transition Report of Foreign Private Issuers
Registration Statement for Securities to be Offered to Employees
Tender Offer Statement by Third Party
Tender Offer Statement by Issuer
Prospectus filed pursuant to Rule 424(b)(5)
Definitive Additional Information Statement
Contested Proxy Solicitation Materials
PRRN14A
Quarterly Holdings Report for Institutional Managers
Schedule 13G - Ownership Report
Amended Schedule 13G - Ownership Report
Annual Report of Proxy Voting Record
Specialized Disclosure Report
Iran Notice
Amended Tender Offer Statement by Third Party
S-8 POS
Free Writing Prospectus